-+ 0.00%
-+ 0.00%
-+ 0.00%

MannKind reports positive Phase 1b INFLO-1 results for inhaled nintedanib in IPF

PUBT·07/29/2026 10:31:05
Listen to the news
MannKind reports positive Phase 1b INFLO-1 results for inhaled nintedanib in IPF
  • MannKind reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis.
  • Trial met its primary goal, showing the inhaled therapy was generally safe and well tolerated, with no serious safety issues.
  • Most patients reported no cough; reported cough was mostly mild and did not drive treatment stoppages.
  • Additional data will be presented at a future conference.
  • Global Phase 2 INFLO-2 is actively enrolling, positioning the program for a larger test of safety and potential efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290630PRIMZONEFULLFEED9799978) on July 29, 2026, and is solely responsible for the information contained therein.